About Dr. Seewaldt
Victoria Seewaldt, MD, is an internationally recognized expert in translational research, the interface between diabetes and cancer, and the health science disparities. Dr. Seewaldt leads a bench to community research program focusing on identifying molecular targets and multi-disciplinary targets for early detection of biologically aggressive cancers and studying the role insulin has on promoting aggressive cancer biology. Dr. Seewaldt has been continuously funded by NIH since 2000 to develop basic/translational research strategies identifying signaling networks that promote cancer initiation to provide early detection of interval breast cancers and reduce cancer health disparities and most recently diabetes. The unique feature of Dr. Seewaldt’s program is that biomarkers identified in the laboratory can be immediately translated to develop novel pharmacologic agents and strategies to reduce cancer health disparities and prevent type-2 diabetes. Dr. Seewaldt is the first generation born in this country; Dr. Seewaldt is a strong advocate for women, particularly women from diverse backgrounds; to this end she was awarded the 2017 NIH/CAP/CURE Champion Mentorship Award. Dr. Seewaldt currently is MPI of a T32 training grant to study the interface of diabetes, metabolism, and cancer. She is also MPI of the P20CA24619 University California, Riverside-City of Hope partnership to build capacity in translational research, drug development focusing on cancer and type-2 diabetes in diverse populations.